Drug intelligence / Profile preview

ceftazidime

Development stage
Approved
Lead developer
GSK
Modality
Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Administration
Intravenous, Intramuscular
01

Overview

Ceftazidime is a third-generation cephalosporin antibiotic with broad-spectrum activity against Gram-negative and some Gram-positive bacteria. It is particularly effective against Pseudomonas aeruginosa and other resistant Gram-negative organisms. The drug acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking essential for cell wall integrity and leading to bacterial lysis. Ceftazidime is administered primarily via intravenous or intramuscular injection and is used in the treatment of serious infections such as pneumonia (including hospital-acquired), meningitis, sepsis, urinary tract infections (UTIs), skin and soft tissue infections, bone and joint infections (such as septic arthritis), intra-abdominal infections including peritonitis (especially in peritoneal dialysis patients), malignant otitis externa, and various other severe or life-threatening conditions caused by susceptible bacteria[1][5][7]. It has high stability against many beta-lactamases produced by Gram-negative bacteria but can be hydrolyzed by extended-spectrum beta-lactamases (ESBLs) or carbapenemases.

Brand names
FortazAnsaidineKefadimTazicefCeptazCefzimZepizidimCeftidimeCeftumax
Other names
头孢他啶ceftazidime pentahydrate
02

Targets

PBP2 (Penicillin-binding protein 2)PBP1b (Penicillin-binding protein 1B)PBP1A (Penicillin-binding protein 1A)

Beyond the preview

Go deeper on ceftazidime.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ceftazidime.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call